通过患者衍生R252C突变的另一个EGFR激活促进癌症进展
Yajuan Zhang1,2, Qizhen Fei3, Yan Li4
1Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Nature communications
|January 21, 2026
概括
细胞外表皮生长因子受体 (EGFR) 突变 (R252C) 通过激活ERK1/2.2驱动癌症. 阿法丁尼布通过这种EGFR变异有效治疗肺癌和质瘤.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 表皮生长因子受体 (EGFR) 的突变与癌症的发展有关.
- 细胞内EGFR突变得到了很好的研究,但细胞外突变的功能不太了解.
- 细胞外EGFR突变在癌症发病过程中的作用需要进一步研究.
研究的目的:
- 为了研究在患有多焦点肺癌和质瘤的患者中发现的细胞外EGFR突变 (R252C) 的功能机制.
- 确定EGFR R252C突变如何影响EGFR二分化,信号和下游通路.
- 评估阿法提尼布对携带EGFR R252C突变的癌症的治疗疗效.
主要方法:
- 在患者衍生的瘤中识别和表征EGFR R252C突变.
- 对EGFR二分化,形状变化和与ERK1/2.2相互作用的分析.
- 在体外和体内研究,以评估突变对瘤细胞增殖和生长的影响.
- 在临床前模型和患者中使用阿法提尼布的治疗反应评估.
主要成果:
- EGFR R252C突变促进了二硫化物介导的EGFR二分化和形状变化.
- EGFR R252C导致缺少自酸化,但增强了与ERK1/2.2的直接相互作用.
- EGFR R252C直接酸化并激活ERK1/2,促进瘤细胞的增殖和生长.
- 阿法丁尼布有效抑制了瘤生长,并延长了患者的无进展生存期.
结论:
- 细胞外EGFR R252C突变通过一种新的机制激活ERK1/2信号传递.
- 这种突变驱动肺癌和质瘤的瘤进展.
- 阿法替尼在治疗EGFR R252C突变癌症方面表现出有效性,突出了其治疗潜力.
相关概念视频
03:03mTOR Signaling and Cancer Progression
4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.7K
01:39Mutations
94.4K
Overview
94.4K
01:35Mutations
44.0K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.0K
02:21Cancers Originate from Somatic Mutations in a Single Cell
14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
00:36Viral Mutations
39.8K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
02:18Alternative RNA Splicing
24.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.7K